Lpa Screening Interpretation Cascade

---
name: lpa-screening-interpretation-cascade
description: Order and interpret lipoprotein(a) [Lp(a)] measurement at least once in a lifetime, apply the risk-enhancer threshold (≥125 nmol/L or ≥50 mg/dL), and run cascade screening of first-degree relatives for premature ASCVD, familial hypercholesterolaemia, or elevated Lp(a) per the 2026 ACC/AHA multisociety dyslipidaemia guideline. Covers the Class 1 lifetime measurement, how elevated Lp(a) affects LLT initiation and intensification, the cascade screening indications, the interaction of Lp(a) with ASCVD risk estimation, and current therapeutic limitations. Use when a clinician asks when to check Lp(a), how often to repeat Lp(a), elevated Lp(a) what next, treatment for high Lp(a), should I screen my patient's family, Lp(a) and statins, cascade screening indications. Grounded in the 2026 ACC/AHA multisociety dyslipidaemia guideline.
---

# Lipoprotein(a) — Screening, Interpretation & Cascade

Lp(a) is a genetically-determined atherogenic lipoprotein with a causal association with ASCVD. The 2026 guideline makes a **Class 1 recommendation to measure Lp(a) at least once in a lifetime** in all adults. Elevated Lp(a) functions as a **risk enhancer** that tips borderline / intermediate patients toward LLT.

---

## Step 1 — Order Lp(a) at least once in every adult's lifetime

**Class 1 — Lp(a) measurement at least once in a lifetime** in all adults.

**Preferred units:** **nmol/L** (particle-based) when available. Mass-based (**mg/dL**) is acceptable but is a less direct measure.

- **Elevated threshold** (risk enhancer): **≥125 nmol/L** OR **≥50 mg/dL**
- **Fasting status does not matter** — Lp(a) is genetically determined and does not change with fasting

**Why "at least once":**

- Lp(a) is 70–90% heritable — it is relatively stable across adult life
- A normal Lp(a) once rarely needs repeating
- An elevated Lp(a) is **persistent** and does not need confirmation / monitoring on serial measurement
- Lp(a) rises in acute inflammation and some pregnancies — defer measurement during acute illness

---

## Step 2 — Interpret the result

| Lp(a) | Interpretation |
|---|---|
| **<75 nmol/L** (or <30 mg/dL) | Normal — low ASCVD contribution; no further action for Lp(a) |
| **75–125 nmol/L** (or 30–49 mg/dL) | Intermediate — some additional ASCVD risk; use clinical judgement |
| **≥125 nmol/L** OR **≥50 mg/dL** | **Elevated — ACTS AS A RISK ENHANCER** per the CPR framework |
| **Very high** (e.g. >180 nmol/L or >70 mg/dL) | Confers risk comparable to familial hypercholesterolaemia; LLT consideration even in low 10-year ASCVD risk |

---

## Step 3 — Use elevated Lp(a) in the CPR framework

**Elevated Lp(a) is a biomarker risk enhancer** (per `dyslipidemia-cpr-framework-2026`). It tips the LLT decision toward treatment in borderline / intermediate PREVENT-ASCVD categories.

**Scenarios:**

| Patient scenario | Action |
|---|---|
| Low 10-year risk (<3%), Lp(a) normal | No LLT; lifestyle |
| Low 10-year risk (<3%), **Lp(a) very high** (e.g. >75 mg/dL / 180 nmol/L) | **Consider LLT despite low 10-year risk** — Lp(a) confers lifetime risk analogous to FH |
| Borderline (3–<5%), Lp(a) elevated | **Enhancer satisfied — favour LLT** |
| Intermediate (5–<10%), Lp(a) elevated | **Enhancer satisfied — supports LLT intensification** |
| High (≥10%), Lp(a) elevated | Already on high-intensity statin; elevated Lp(a) supports **aggressive LLT** (consider PCSK9i add-on) |
| Any risk category, Lp(a) elevated + concomitant FH | High / very-high risk — treat aggressively with high-intensity statin ± PCSK9i |

**Elevated Lp(a) also triggers:**

- **Cascade screening** of first-degree relatives — see Step 4
- Consideration of **more aggressive LDL goals**
- **Shared decision-making** about lifelong statin ± non-statin therapy

---

## Step 4 — Cascade screening of first-degree relatives

**Cascade screening of first-degree relatives is recommended** when the index case has any of:

- **Elevated Lp(a)** (≥125 nmol/L or ≥50 mg/dL)
- **Premature ASCVD** (men <55 y, women <65 y)
- **Familial hypercholesterolaemia** (LDL ≥190 mg/dL in adults, or clinical / genetic diagnosis)

**What to screen in relatives:**

- Full lipid panel including TC, HDL-C, TG, LDL-C (Martin-Hopkins or Sampson calculation), non-HDL-C
- **Lp(a)** — once per lifetime per relative
- Genetic testing if presumed FH

**Who counts as first-degree:** parents, siblings, children ≥9 years of age (universal paediatric lipid screening ages 9–11 captures them anyway)

---

## Step 5 — Lp(a) in children and adolescents

- **Universal paediatric lipid screening at ages 9–11** (ADA / NHLBI endorsed) — Lp(a) can be measured as part of this
- **Cascade screening of children** when a parent has premature ASCVD, FH, or elevated Lp(a) — do the lipid panel including Lp(a) in the child
- **After adolescence**, screening every 5 years as part of ongoing risk assessment

Early identification allows for lifestyle intervention, cascade screening of second-degree relatives, and age-appropriate LLT discussions in adolescence.

---

## Step 6 — Treatment considerations for elevated Lp(a)

**Current reality: there is no approved Lp(a)-specific therapy that has demonstrated outcome benefit.**

Options:

- **Statins** — do NOT significantly lower Lp(a) (may slightly increase in some patients), but still indicated for LDL management given the ASCVD risk conferred by elevated Lp(a)
- **PCSK9 inhibitors** (alirocumab, evolocumab) — lower Lp(a) by ~20–30%; included in LLT optimisation per LDL goals
- **Niacin** — lowers Lp(a) ~20–30% but **no outcome benefit** when added to statin; not recommended for Lp(a)-specific therapy
- **Lipoprotein apheresis** — reserved for severe elevations with progressive ASCVD; limited availability
- **Investigational**: antisense oligonucleotides (e.g. pelacarsen) and siRNA (e.g. olpasiran, lepodisiran, zerlasiran) targeting apo(a) — in Phase 3 cardiovascular outcome trials. **Not yet approved.**

**Practical approach:**

1. **Confirm elevated Lp(a)** — one measurement is enough
2. **Aggressively treat conventional lipids** — LDL, non-HDL, ApoB to the lowest achievable goals
3. **Cascade screen** relatives (Step 4)
4. **Lifestyle optimisation** — diet, exercise, weight, tobacco
5. **Shared decision-making** — explain that Lp(a) itself does not currently have a specific treatment with proven outcome benefit, but conventional lipid management reduces overall ASCVD risk
6. **Document** elevated Lp(a) in the problem list for future care continuity

---

## Guardrails

- **Lp(a) is a lifetime measurement** — a normal Lp(a) does not need repeating in a stable patient. Do NOT order it serially
- **An elevated Lp(a) does not need confirmation** — one measurement is sufficient. Repeat testing of an elevated value is low-yield
- **Measure in nmol/L when available** — mass units (mg/dL) are affected by apo(a) isoform size and are less reliable for cross-patient comparison
- **Defer measurement during acute illness or acute inflammation** — Lp(a) rises transiently; wait until stable
- **Elevated Lp(a) by itself is not an automatic Class-1 LLT indication** — it is a risk enhancer that tips borderline / intermediate decisions. Very high Lp(a) (>75 mg/dL or 180 nmol/L) does strongly favour LLT even in low 10-year risk
- **Lp(a) does NOT change with lifestyle** — do not promise patients that diet and exercise will lower it. They won't. The purpose of lifestyle advice in the setting of high Lp(a) is lowering OVERALL ASCVD risk
- **Statins do not lower Lp(a)** meaningfully; sometimes they raise it slightly. Do not avoid statins because of this — they still reduce overall ASCVD risk via LDL
- **Niacin is NOT recommended** for Lp(a) despite its biochemical effect — no outcome benefit when added to statin
- **Cascade screening is often missed** — the index case comes in and leaves without triggering family screening. Build this into the workflow at the point of result delivery
- **Investigational Lp(a) therapies are promising but NOT yet approved** — do not promise patients these drugs are available
- **Do not screen Lp(a) more frequently than once** unless there is a specific clinical reason (e.g. post-pregnancy restabilisation)

---

## Related MD2SKILL skills

- `prevent-ascvd-risk-calculator-interpretation` — Lp(a) feeds into the risk discussion
- `dyslipidemia-cpr-framework-2026` — Lp(a) is a biomarker risk enhancer in the Personalize step
- `dyslipidemia-ldl-treatment-goals-2026` — elevated Lp(a) supports more aggressive LDL / non-HDL / ApoB goals

---

## Sources

**Primary:** 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Multisociety Guideline on the Management of Dyslipidaemia.

**Review used for extraction:** Abramov D et al. **Primary Prevention of Dyslipidemia: 10 Practice-Changing Takeaways from the 2026 ACC/AHA Multisociety Guideline.** *Current Atherosclerosis Reports.* 2026;28:63. DOI: 10.1007/s11883-026-01437-9. Section "Key Message 2: Quantification of Dyslipidemia" (Lp(a) Class 1 recommendation and cascade screening).